Issue link: http://osercommunicationsgroup.uberflip.com/i/960900
AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS Kimberly Oser Publisher Jules Denton-Card Senior Associate Publisher Lorrie Baumann Editorial Director Jeanie Catron • JoEllen Lowry • Karrie Welborn Associate Editors Yasmine Brown Art Director Jonathan Schieffer Graphic Designer Caitlyn McGrath • Susan Stein Customer Service Managers Jay Watson • Hannah Stefanovich • Margaret Oser Show Logistics & Distribution Marcos Morhaim Senior Account Manager Andrea Hartnett • Anthony Socci Account Managers Tara Neal Director of Operations Enrico Cecchi European Sales Chain Drugstore Daily is published by Oser Communications Group ©2018 All rights reserved. Executive and editorial offices at: 1877 N. Kolb Road, Tucson, AZ 85715 520.721.1300/Fax: 520.721.6300 European offices located at Lungarno Benvenuto Cellini, 11, 50125 Florence, Italy www.osercommunicationsgroup.com Lee M. Oser Founder Chain Drugstore Daily Sunday, April 22, 2018 4 Hikma Announces New Leadership Roles Hikma Pharmaceuticals PLC has announced its Board of Directors has appointed Sigurdur (Siggi) Olafsson as Chief Executive Officer. Olafsson will also join Hikma's Board of Directors as an Executive Director, subject to election at the next annual general meeting in May 2018. Said Darwazah, Hikma's cur- rent Chairman and Chief Executive Officer, will assume the position of Executive Chairman. These changes are effective immediately. With over 25 years of diverse phar- maceutical experience, Olafsson brings substantial commercial and operational capabilities and has a strong track record of driving performance and delivering growth. He has held many leadership roles at some of the world's largest generic pharmaceutical companies. "We are delighted that Siggi is join- ing Hikma as our new CEO," said Said Darwazah. "He brings a wealth of phar- maceutical and leadership experience and we are confident that his deep sector knowledge, paired with his proven ability to drive growth, will help us achieve our ambitions for the business." As Chief Executive Officer, Olafsson will be responsible for the effective development and execution of Hikma's corporate strategy, focusing on opportunities to accelerate growth of the global business. All members of Hikma's Executive Committee will report to Olafsson, who will report to Darwazah. He will initially be based in the US before relocat- ing to Hikma's head office in London. "I am looking for- ward to leading the Hikma team, building on the strong legacy the business has estab- lished, particularly in the US and MENA," said Olafsson. "I share Said's confidence in the future of this business, and believe that we have the potential to deliver substantial value to our cus- tomers, employees, investors and the wider community." As Executive Chairman, Said will lead the Board of Directors. He will guide, oversee and engage with the Chief Executive in setting and delivering the Amneal: Accelerating Growth from All Angles The Amneal/Impax combination creates the fifth largest generic pharmaceuticals company in the United States. The increased scale and product diversifica- tion, along with a growing specialty fran- chise, positions Amneal well for contin- ued growth. A look at last year's metrics demon- strate the company's commitment to strengthening its portfolio and pipeline. Amneal launched a total of 34 new prod- ucts in 2017. Two of these launches were nasal sprays, which added yet another dosage form to Amneal's full suite of capabilities. The total also included nine injectables, further expanding the compa- ny's institutional offering. Regulatory activity was robust, as well, with Amneal filing 48 ANDAs and receiving 45 FDA approvals. All this was accomplished within a 12-month timeframe, coinciding with the company's milestone celebra- tion of 10 years in the market. Building off the momentum of 2017, this calen- dar year appears to be off to a strong start for Amneal. A mere 2 ½ months into 2018, Amneal had already launched seven new generic products and received approval for nine ANDAs. At the time of writing, five more products were on track for launch before the end of April. In other news, Amneal continues to work toward combining with Impax, a merger expected to grow the Amneal portfolio to approximately 200 marketed Continued on Page 29 Continued on Page 29